Cargando…

The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review

BACKGROUND: COVID-19 vaccines are required for individuals with myasthenia gravis (MG), as these patients are more likely to experience severe pneumonia, myasthenia crises, and higher mortality rate. However, direct data on the safety of COVID-19 vaccines in patients with MG are lacking, which resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Siyang, Tian, Yukun, Meng, Linghao, Fang, Ruiying, Chang, Weiqian, Yang, Yajing, Li, Shaohong, Shen, Qiqi, Ni, Jinxia, Zhu, Wenzeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812949/
https://www.ncbi.nlm.nih.gov/pubmed/36618419
http://dx.doi.org/10.3389/fimmu.2022.1103020
_version_ 1784863825882775552
author Peng, Siyang
Tian, Yukun
Meng, Linghao
Fang, Ruiying
Chang, Weiqian
Yang, Yajing
Li, Shaohong
Shen, Qiqi
Ni, Jinxia
Zhu, Wenzeng
author_facet Peng, Siyang
Tian, Yukun
Meng, Linghao
Fang, Ruiying
Chang, Weiqian
Yang, Yajing
Li, Shaohong
Shen, Qiqi
Ni, Jinxia
Zhu, Wenzeng
author_sort Peng, Siyang
collection PubMed
description BACKGROUND: COVID-19 vaccines are required for individuals with myasthenia gravis (MG), as these patients are more likely to experience severe pneumonia, myasthenia crises, and higher mortality rate. However, direct data on the safety of COVID-19 vaccines in patients with MG are lacking, which results in hesitation in vaccination. This scoping was conducted to collect and summarize the existing evidence on this issue. METHODS: PubMed, Cochrane Library, and Web of Science were searched for studies using inclusion and exclusion criteria. Article titles, authors, study designs, demographics of patients, vaccination information, adverse events (AEs), significant findings, and conclusions of included studies were recorded and summarized. RESULTS: Twenty-nine studies conducted in 16 different countries in 2021 and 2022 were included. Study designs included case report, case series, cohort study, cross-sectional study, survey-based study, chart review, and systemic review. A total of 1347 patients were included. The vaccines used included BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, inactivated vaccines, and recombinant subunit vaccines. Fifteen case studies included 48 patients reported that 23 experienced new-onset, and five patients experienced flare of symptoms. Eleven other types of studies included 1299 patients reported that nine patients experienced new-onset, and 60 participants experienced flare of symptoms. Common AEs included local pain, fatigue, asthenia, cephalalgia, fever, and myalgia. Most patients responded well to treatment without severe sequelae. Evidence gaps include limited strength of study designs, type and dose of vaccines varied, inconsistent window of risk and exacerbation criteria, limited number of participants, and lack of efficacy evaluation. CONCLUSION: COVID-19 vaccines may cause new-onset or worsening of MG in a small proportion of population. Large-scale, multicenter, prospective, and rigorous studies are required to verify their safety.
format Online
Article
Text
id pubmed-9812949
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98129492023-01-06 The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review Peng, Siyang Tian, Yukun Meng, Linghao Fang, Ruiying Chang, Weiqian Yang, Yajing Li, Shaohong Shen, Qiqi Ni, Jinxia Zhu, Wenzeng Front Immunol Immunology BACKGROUND: COVID-19 vaccines are required for individuals with myasthenia gravis (MG), as these patients are more likely to experience severe pneumonia, myasthenia crises, and higher mortality rate. However, direct data on the safety of COVID-19 vaccines in patients with MG are lacking, which results in hesitation in vaccination. This scoping was conducted to collect and summarize the existing evidence on this issue. METHODS: PubMed, Cochrane Library, and Web of Science were searched for studies using inclusion and exclusion criteria. Article titles, authors, study designs, demographics of patients, vaccination information, adverse events (AEs), significant findings, and conclusions of included studies were recorded and summarized. RESULTS: Twenty-nine studies conducted in 16 different countries in 2021 and 2022 were included. Study designs included case report, case series, cohort study, cross-sectional study, survey-based study, chart review, and systemic review. A total of 1347 patients were included. The vaccines used included BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, inactivated vaccines, and recombinant subunit vaccines. Fifteen case studies included 48 patients reported that 23 experienced new-onset, and five patients experienced flare of symptoms. Eleven other types of studies included 1299 patients reported that nine patients experienced new-onset, and 60 participants experienced flare of symptoms. Common AEs included local pain, fatigue, asthenia, cephalalgia, fever, and myalgia. Most patients responded well to treatment without severe sequelae. Evidence gaps include limited strength of study designs, type and dose of vaccines varied, inconsistent window of risk and exacerbation criteria, limited number of participants, and lack of efficacy evaluation. CONCLUSION: COVID-19 vaccines may cause new-onset or worsening of MG in a small proportion of population. Large-scale, multicenter, prospective, and rigorous studies are required to verify their safety. Frontiers Media S.A. 2022-12-22 /pmc/articles/PMC9812949/ /pubmed/36618419 http://dx.doi.org/10.3389/fimmu.2022.1103020 Text en Copyright © 2022 Peng, Tian, Meng, Fang, Chang, Yang, Li, Shen, Ni and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Peng, Siyang
Tian, Yukun
Meng, Linghao
Fang, Ruiying
Chang, Weiqian
Yang, Yajing
Li, Shaohong
Shen, Qiqi
Ni, Jinxia
Zhu, Wenzeng
The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review
title The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review
title_full The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review
title_fullStr The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review
title_full_unstemmed The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review
title_short The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review
title_sort safety of covid-19 vaccines in patients with myasthenia gravis: a scoping review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812949/
https://www.ncbi.nlm.nih.gov/pubmed/36618419
http://dx.doi.org/10.3389/fimmu.2022.1103020
work_keys_str_mv AT pengsiyang thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT tianyukun thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT menglinghao thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT fangruiying thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT changweiqian thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT yangyajing thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT lishaohong thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT shenqiqi thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT nijinxia thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT zhuwenzeng thesafetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT pengsiyang safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT tianyukun safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT menglinghao safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT fangruiying safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT changweiqian safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT yangyajing safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT lishaohong safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT shenqiqi safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT nijinxia safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview
AT zhuwenzeng safetyofcovid19vaccinesinpatientswithmyastheniagravisascopingreview